bgb-283
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT02610361)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
BRAF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545246 ↗
Also known as
- bgb-283
- bgb-283
- bgb-283
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03905148 | Phase 1/Phase 2 (Phase 2) | Mar 28, 2019 | BeOne Medicines, SpringWorks Therapeutics, Inc. |
| NCT03641586 | Phase 1 | Oct 31, 2015 | BeOne Medicines |
| NCT02610361 | Phase 1 | Nov 1, 2013 | BeOne Medicines |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeOne Medicines | For profit | 3 | 3 | 2 | 2013 |
| SpringWorks Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1